Rocket Pharmaceuticals is a Buy, with strong catalysts, undervalued programs, and significant upside. Click here to read my analysis of RCKT stock.

BAAR, Switzerland, Feb. 8, 2021 /PRNewswire/ -- Orpha Labs AG today announced its compassionate use program to make ORL-101 available to physicians providing care for Leukocyte Adhesion Deficiency ...